Liver Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Liver transplantation is the conventional therapy used in various liver diseases. The liver has the unique ability to regenerate or grow, unlike any other organ in the body. A liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. The immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.
The liver transplant rejection pipeline market research report provides comprehensive information on the therapeutics under development for liver transplant rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for liver transplant rejection and features dormant and discontinued projects.
Key Targets in the Liver Transplant Rejection Pipeline Products Market
The key targets in the liver transplant rejection pipeline products market are Calcineurin, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing MHC Class I Antigen, and Complement C5.
Liver Transplant Rejection Pipeline Products Market Analysis by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Liver Transplant Rejection Pipeline Products Market
The key mechanisms of action in the liver transplant rejection pipeline products market are Calcineurin Inhibitor, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Complement C5 Inhibitor, Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20, and Cytotoxic To Cells Expressing MHC Class I Antigen.
Liver Transplant Rejection Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Liver Transplant Rejection Pipeline Products Market
The key routes of administration in the liver transplant rejection pipeline products market are intravenous, parenteral, oral, inhalational, intraarterial, and intracerebral.
Liver Transplant Rejection Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Liver Transplant Rejection Pipeline Products Market
The key molecule types in the liver transplant rejection pipeline products market are cell therapy, monoclonal antibody, small molecule, fusion protein, gene therapy, and gene-modified cell therapy.
Liver Transplant Rejection Pipeline Products Market Analysis by Molecule Types
For more molecule-type insights, download a free report sample
Key Companies in the Liver Transplant Rejection Pipeline Products Market
Some of the major companies in the liver transplant rejection pipeline products market are Junten Bio Co Ltd, Alexion Pharmaceuticals Inc, Astellas Pharma Inc, Dompe Farmaceutici SpA, Genexine Inc, and ITB-Med AB.
Liver Transplant Rejection Pipeline Products Market Analysis by Companies
For more company insights, download a free report sample
Key Universities in the Liver Transplant Rejection Pipeline Products Market
Some of the key universities in the liver transplant rejection pipeline products market are King’s College London, Helmholtz Center Munich German Research Center for Health and Environment GmbH, Huazhong University of Science & Technology, Nanjing Medical University, and the University of Pittsburgh.
Liver Transplant Rejection Pipeline Products Market Analysis by Universities
For more university insights, download a free report sample
Liver Transplant Rejection Pipeline Products Market Report Overview
Key Targets | Calcineurin, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing MHC Class I Antigen, and Complement C5 |
Key Mechanisms of Action | Calcineurin Inhibitor, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Complement C5 Inhibitor, Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20, and Cytotoxic to Cells Expressing MHC Class I Antigen |
Key Routes of Administration | Intravenous, Parenteral, Oral, Inhalational, Intraarterial, and Intracerebral |
Key Molecule Type | Cell Therapy, Monoclonal Antibody, Small Molecule, Fusion Protein, Gene Therapy, and Gene-Modified Cell Therapy |
Major Companies | Junten Bio Co Ltd, Alexion Pharmaceuticals Inc, Astellas Pharma Inc, Dompe Farmaceutici SpA, Genexine Inc, and ITB-Med AB |
Major Universities | King’s College London, Helmholtz Center Munich German Research Center for Health and Environment GmbH, Huazhong University of Science & Technology, Nanjing Medical University, and University of Pittsburgh |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of liver transplant rejection (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for liver transplant rejection (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in liver transplant rejection (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates liver transplant rejection (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for liver transplant rejection (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for liver transplant rejection (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding liver transplant rejection (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Astellas Pharma Inc
Dompe Farmaceutici SpA
Genexine Inc
ITB-Med AB
Junten Bio Co Ltd
Novartis AG
Pharmapraxis
Quell Therapeutics Ltd
Veloxis Pharmaceuticals AS
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the liver transplant rejection products market?
The key targets in the liver transplant rejection pipeline products market are Calcineurin, C-X-C Chemokine Receptor Type 1, C-X-C Chemokine Receptor Type 2, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing MHC Class I Antigen, and Complement C5.
-
What are the key mechanisms of action in the liver transplant rejection pipeline products market?
The key mechanisms of action in the liver transplant rejection pipeline products market are Calcineurin Inhibitor, C-X-C Chemokine Receptor Type 1 Antagonist, C-X-C Chemokine Receptor Type 2 Antagonist, Complement C5 Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, and Cytotoxic To Cells Expressing MHC Class I Antigen.
-
What are the key routes of administration in the liver transplant rejection pipeline products market?
The key routes of administration in the liver transplant rejection pipeline products market are intravenous, parenteral, oral, inhalational, intraarterial, and intracerebral.
-
What are the key molecule types in the liver transplant rejection pipeline products market?
The key molecule types in the liver transplant rejection pipeline products market are cell therapy, monoclonal antibody, small molecule, fusion protein, gene therapy, and gene-modified cell therapy.
-
Which are the major companies in the liver transplant rejection pipeline products market?
Some of the major companies in the liver transplant rejection pipeline products market are Junten Bio Co Ltd, Alexion Pharmaceuticals Inc, Astellas Pharma Inc, Dompe Farmaceutici SpA, Genexine Inc, and ITB-Med AB.
-
Which are the major universities in the liver transplant rejection pipeline products market?
Some of the major universities in the liver transplant rejection pipeline products market are King’s College London, Helmholtz Center Munich German Research Center for Health and Environment GmbH, Huazhong University of Science & Technology, Nanjing Medical University, and the University of Pittsburgh.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.